



(51) International Patent Classification:

C07D 231/56 (2006.01) **A61K 31/416** (2006.01)
C07D 249/18 (2006.01) **A61K 31/4192** (2006.01)
C07D 409/06 (2006.01) **A61P 35/00** (2006.01)
C07D 401/06 (2006.01)

(21) International Application Number:

PCT/US2011/051845

(22) International Filing Date:

15 September 2011 (15.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/383,659	16 September 2010 (16.09.2010)	US
61/410,727	5 November 2010 (05.11.2010)	US
61/446,967	25 February 2011 (25.02.2011)	US
GB1104288.4	15 March 2011 (15.03.2011)	GB

(71) Applicant (for all designated States except US):
ARAGON PHARMACEUTICALS, INC. [US/US];
12780 El Camino Real, Suite 301, San Diego, CA 92130
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Nicholas, D.** [US/US]; 1204 Beryl Street, San Diego, CA 92109 (US). **KAHRAMAN, Mehmet** [TR/US]; 8617 Via Mal-lorca Unit E, La Jolla, CA 92037 (US). **GOVEK, Steven, P.** [US/US]; 13216 Via Santillana, San Diego, CA 92129 (US). **NAGASAWA, Johnny, Y.** [JP/US]; 8525 Park Run Road, San Diego, CA 92129 (US). **LAI, Andilly, G.** [US/US]; 7360 Calle Cristobal Unit 112, San Diego, CA 92126 (US). **JULIEN, Jackaline, D.** [US/US]; 517 ½ Stratford Ct., Del Mar, CA 92014 (US). **HERBERT, Mark R.** [US/US]; 4180 Amoroso St., San Diego, CA 92111 (US). **BONNEFOUS, Celine** [US/US]; 4425 Via Sepulveda, Unit #3, San Diego, CA 92122 (US). **DOU-**

GLAS, Karensa L. [US/US]; 4050 Rosenda Court Unit #244, San Diego, CA 92122 (US).

(74) Agents: **HOSTETLER, Michael, J. Phd, Esq.** et al.;
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road,
Palo Alto, CA 94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

(57) Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

